Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1192 participants.

Also called NCT07263308

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,192 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07263308
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07263308. Randomized; no masking; primary purpose treatment. Start 2025-12-18 (actual); primary completion 2027-06-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
Acronym
ARISE-2
Condition
Acute Ischemic Stroke
Intervention (Drug)
Albumin
Intervention (Procedure)
Endovascular treatment
Lead sponsor
Capital Medical University (class: other)

Record details

Record id
cardio:ct-nct07263308
Content hash
d6a29c9ba2d5590f01e8d940a03e77f03399aa3c9871b7262a527011af3423d4